|Bid||0.00 x 1100|
|Ask||126.79 x 1400|
|Day's range||115.34 - 119.56|
|52-week range||78.44 - 131.73|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||49.70|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) closed at $118.26 in the latest trading session, marking a -1.83% move from the prior day.